Suzhou Ribo Life Science (HKEX: 6938) has announced the development of its RiboPepSTAR™ platform, marking a significant breakthrough in RNA therapeutics. The new technology enables the targeted delivery of small interfering RNA (siRNA) to multiple organs beyond the liver, addressing a major technical hurdle in the industry. Traditionally, siRNA treatments have been limited by delivery constraints to liver-related diseases. The company was invited to present its findings and technological advancements at a specialized RNA-focused conference. This expansion into extrahepatic delivery significantly enhances the potential value of Ribo's drug pipeline and therapeutic reach. Investors view this milestone as a positive indicator of the company's innovation capabilities within the competitive biotech sector.
Sign up free to access this content
Create Free Account